Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2026-02-20 @ 12:45 PM
Study NCT ID:
NCT01752205
Status:
UNKNOWN
Last Update Posted:
2012-12-19
First Post:
2012-12-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma
Sponsor:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Organization:
Study Overview
Official Title:
A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma
Status:
UNKNOWN
Status Verified Date:
2012-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ESCC-307PLAH
Brief Summary:
The purpose of this study is to test the safety and effectiveness of erlotinib and chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous cancer .
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: